TNYA — Tenaya Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027
Brief: Tenaya Therapeutics Q4 Net Income USD -20.175 Million Vs. IBES Estimate USD -22 Million
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments
Brief: Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics
Brief: Tenaya Therapeutics Announces 2026 Strategic Priorities
U.S. STOCKS ON THE MOVE-GE Aerospace
Tenaya Therapeutics slumps after $60 million share sale
Tenaya Therapeutics slides after launching stock offering
Brief: Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition
US FDA places clinical hold on Tenaya gene therapy trial for rare heart disease (updated)
Brief: Tenaya Therapeutics Inc - FDA Places Clinical Hold On Tenaya's Mypeak-1 Trial - SEC Filing
US FDA places clinical hold on Tenaya Therapeutics' gene therapy
Brief: Tenaya Therapeutics Reports Inducement Grants
Tenaya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tenaya Therapeutics Q2 Net Income USD -23.283 Million Vs. IBES Estimate USD -25.9 Million
Tenaya Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview